Everest Medicines Ltd. held its Annual General Meeting on June 27, 2025. The proposals included the adoption of the audited consolidated financial statements for the year ended December 31, 2024, along with the reports from the directors and independent auditor. All proposed resolutions were approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.